PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
September 10, 2026˜The œmedical letter on drugs and therapeutics/˜The œmedical letter

mFLUSIVA — An mRNA-Based Influenza Vaccine

View Full Paper
Ask AI
Bookmark
Share

Discussion

Loading...

Member takes

Overview

Regulatory approval reports the licensure of the first mRNA influenza vaccine in older adults, highlighting the clinical expansion of mRNA platforms.

Key Points

  • To announce the FDA licensure and intended rollout of mFLUSIVA, the first mRNA-based influenza vaccine approved in the United States.
  • FDA regulatory evaluation and approval of mFLUSIVA (Moderna) for the prevention of influenza.
  • Indication targeted to adults aged 50 years and older, scheduled for introduction in the 2026–2027 influenza season.
  • mFLUSIVA received FDA approval as the first mRNA-based influenza vaccine available in the United States for adults ≥50 years old.
  • The authorization broadens licensed US mRNA vaccine indications alongside three COVID-19 vaccines and one RSV vaccine.

Cite This Study

A 2026 study studied this question.

synapsesocial.com/papers/6aa27b9a58559d80afc74e30https://doi.org/10.58347/tml.2026.1763b
View Full Paper
Ask AI
Bookmark
Share